Research at Iteos Belgium SA has led to the discovery of macrocyclic compounds acting as equilibrative nucleoside transporter ENT1 inhibitors and reported to be useful for the treatment of cancer.
2-Oxo-3-azabicyclo[3.1.0]hexane derivatives acting as ketohexokinase (KHK) inhibitors have been reported in a recent Hua Medicine Ltd. patent as potentially useful for the treatment of diabetes, fibrosis, obesity, neurological, metabolic, gastrointestinal, cardiovascular and renal diseases, among others.
GSK plc and Ideaya Biosciences Inc. have jointly developed cyclic vinyl sulfone compounds acting as Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors that are reported to be useful for the treatment of cancer.
Merck Sharp & Dohme Corp. researchers have patented targeted activator of cell kill (TACK) compounds acting as Gag polyprotein (HIV-1)/protein Pol dimerization inducers and thus reported to be useful for the treatment of HIV infection.
Leucine-rich repeat kinase 2 (LRRK2; Dardarin) inhibitors have been detailed in a recent Merck Sharp & Dohme Corp. patent and reported to be useful for the treatment of Parkinson’s disease, among others.
Crinetics Pharmaceuticals Inc. has reported parathyroid hormone PTH1 receptor antagonists potentially useful for the treatment of kidney stones, osteoporosis, cardiovascular disorders, cognitive disorders, primary hyperparathyroidism and secondary hyperparathyroidism.
Research at Incyte Corp. has led to the development of pyrazoloquinoline derivatives acting as GTPase KRAS (G12C mutant) inhibitors and reported to be useful for the treatment of cancer, inflammatory and immunological disorders.
Viva Star Biosciences (Suzhou) Co. Ltd. has identified substituted sulfonylurea compounds acting as NLRP3 inflammasome inhibitors and reported to be useful for the treatment of cryopyrin-associated periodic syndrome, multiple sclerosis, atherosclerosis, type 2 diabetes, osteoarthritis, cancer, Alzheimer’s and Parkinson’s disease.
RSS